Gossamer Bio, Inc. (GOSS)

US — Healthcare Sector
Peers: BMEA  STOK  AKRO  FIXX  REPL  NVCT  LYRA  KRON  PASG  BDTX  TCRR  HARP  ALEC  TERN  AMLX  ABOS  INZY  XFOR  BCEL  FDMT 

Automate Your Wheel Strategy on GOSS

With Tiblio's Option Bot, you can configure your own wheel strategy including GOSS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GOSS
  • Rev/Share 0.5493
  • Book/Share -0.0276
  • PB -40.2829
  • Debt/Equity -32.3094
  • CurrentRatio 5.7125
  • ROIC -0.2399

 

  • MktCap 252305220.0
  • FreeCF/Share -0.4729
  • PFCF -2.3522
  • PE -4.9137
  • Debt/Assets 0.7197
  • DivYield 0
  • ROE -1.2898

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
GOSS
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral

Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 …

Read More
image for news Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GOSS
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio.

Read More
image for news Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
GOSS
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.

Read More
image for news Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

About Gossamer Bio, Inc. (GOSS)

  • IPO Date 2019-02-08
  • Website https://www.gossamerbio.com
  • Industry Biotechnology
  • CEO Mr. Faheem Hasnain
  • Employees 144

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.